S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The single greatest medical breakthrough of all time? (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The single greatest medical breakthrough of all time? (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The single greatest medical breakthrough of all time? (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The single greatest medical breakthrough of all time? (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
NASDAQ:CTIC

CTI BioPharma (CTIC) Stock Forecast, Price & News

$9.05
0.00 (0.00%)
(As of 06/5/2023 ET)
Compare
Today's Range
$9.04
$9.05
50-Day Range
$4.08
$9.05
52-Week Range
$4.01
$9.06
Volume
3.07 million shs
Average Volume
4.57 million shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.29

CTI BioPharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
13.7% Upside
$10.29 Price Target
Short Interest
Healthy
6.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of CTI BioPharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.25) to $0.34 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

374th out of 986 stocks

Pharmaceutical Preparations Industry

171st out of 478 stocks


CTIC stock logo

About CTI BioPharma (NASDAQ:CTIC) Stock

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CTIC Stock News Headlines

Stifel Nicolaus upgrades CTI BioPharma (CTIC) to a Hold
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
JMP Securities Keeps Their Hold Rating on CTI BioPharma (CTIC)
Lithium Has Boomed And This American Stock Is Ready..
Lithium Has Been On A Crazy Rally Over The Last 3 Year's And This Stock Could Be Next!
SVB Securities downgrades CTI BioPharma (CTIC) to a Hold
The Latest Analyst Ratings for CTI BioPharma
See More Headlines

CTIC Price History

CTIC Company Calendar

Last Earnings
3/06/2023
Today
6/05/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTIC
Previous Symbol
NASDAQ:CTICD
Employees
22
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$10.29
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+13.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
10 Analysts

Profitability

Net Income
$-92,990,000.00
Pretax Margin
-91.38%

Debt

Sales & Book Value

Annual Sales
$53 million
Book Value
($0.14) per share

Miscellaneous

Free Float
121,844,000
Market Cap
$1.19 billion
Optionable
Optionable
Beta
0.83

Social Links


Key Executives

  • Adam R. CraigAdam R. Craig
    President, CEO, Director & Chief Medical Officer
  • David H. Kirske
    CFO, Secretary & Executive Vice President
  • Jim Fong
    Chief Commercial Officer & Executive VP
  • John Volpone
    Chief of Staff & Executive Vice President













CTIC Stock - Frequently Asked Questions

Should I buy or sell CTI BioPharma stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last twelve months. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CTIC shares.
View CTIC analyst ratings
or view top-rated stocks.

What is CTI BioPharma's stock price forecast for 2023?

10 brokerages have issued twelve-month price targets for CTI BioPharma's shares. Their CTIC share price forecasts range from $8.00 to $13.00. On average, they expect the company's stock price to reach $10.29 in the next year. This suggests a possible upside of 13.7% from the stock's current price.
View analysts price targets for CTIC
or view top-rated stocks among Wall Street analysts.

How have CTIC shares performed in 2023?

CTI BioPharma's stock was trading at $6.01 on January 1st, 2023. Since then, CTIC shares have increased by 50.6% and is now trading at $9.05.
View the best growth stocks for 2023 here
.

Are investors shorting CTI BioPharma?

CTI BioPharma saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 8,080,000 shares, a decline of 33.6% from the April 30th total of 12,170,000 shares. Based on an average daily trading volume, of 5,760,000 shares, the days-to-cover ratio is currently 1.4 days.
View CTI BioPharma's Short Interest
.

When is CTI BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CTIC earnings forecast
.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp. (NASDAQ:CTIC) released its quarterly earnings results on Monday, March, 6th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biopharmaceutical company earned $21.08 million during the quarter, compared to the consensus estimate of $24.88 million. During the same period in the prior year, the business posted ($0.38) earnings per share.

When did CTI BioPharma's stock split?

CTI BioPharma's stock reverse split on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is James A. Bianco's approval rating as CTI BioPharma's CEO?

8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of CTI BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

Who are CTI BioPharma's major shareholders?

CTI BioPharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (9.43%), Rubric Capital Management LP (6.80%), BlackRock Inc. (5.39%), Stonepine Capital Management LLC (4.96%), Bain Capital Life Sciences Investors LLC (3.57%) and Bank of America Corp DE (2.66%). Insiders that own company stock include Adam R Craig, Bvf Partners L P/Il, David Kirske, James K Fong, Michael A Metzger and Orbimed Advisors Llc.
View institutional ownership trends
.

How do I buy shares of CTI BioPharma?

Shares of CTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $9.05.

How much money does CTI BioPharma make?

CTI BioPharma (NASDAQ:CTIC) has a market capitalization of $1.19 billion and generates $53 million in revenue each year. The biopharmaceutical company earns $-92,990,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The official website for the company is www.ctibiopharma.com. The biopharmaceutical company can be reached via phone at (206) 282-7100, via email at invest@ctibiopharma.com, or via fax at 206-284-6206.

This page (NASDAQ:CTIC) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -